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Platelet-derived growth factor (PDGF)-BB and PDGF-DD
mediate mesangial cell proliferation in vitro and in vivo. While
PDGF-BB is a ligand for the PDGF a- and b-receptor chains,
PDGF-DD binds more selectively to the b-chain, suggesting
potential differences in the biological activities. Signal
transduction and regulation of gene expression induced by
PDGF-BB and -DD were compared in primary human
mesangial cells (HMCs), which expressed PDGF a- and
b-receptor subunits. The growth factor concentrations used
were chosen based on their equipotency in inducing HMCs
proliferation and binding to the bb-receptor. Both growth
factors, albeit at different concentrations induced
phosphorylation and activation of extracellular signal-
regulated kinase 1 (ERK1) and ERK2. In addition, PDGFs led to
the phosphorylation and activation of signal transducers and
activators of transcription 1 (STAT1) and STAT3. HMCs
proliferation induced by either PDGF-BB or -DD could be
blocked by signal transduction inhibitors of the
mitogen-activated protein kinase-, Janus kinase (JAK)/STAT-,
or phosphatidyl-inositol 3-kinase pathways. Using a gene
chip array and subsequent verification by real-time reverse
transcriptase (RT)-polymerase chain reaction, we found that
in HMC genes for matrix metalloproteinase 13 (MMP-13) and
MMP-14 and, to a low extent, cytochrome B5 and cathepsin L
were exclusively regulated by PDGF-BB, whereas no exclusive
gene regulation was detected by PDGF-DD. However, at the
protein level, both MMP-13 and -14 were equally induced by
PDGF-BB and -DD. PDGF-BB and -DD effect similar biological
responses in HMCs albeit at different potencies. Rare
apparently differential gene regulation did not result in
different protein expression, suggesting that in HMCs both
PDGFs exert their biological activity almost exclusively via the
PDGF b-receptor.
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Platlet-derived growth factor (PDGF)-A and -B are secreted
as homo- or heterodimers, bind to and induce PDGF
receptor dimers composed of a- and/or b-chains. Two novel
PDGF isoforms, PDGF-C and -D, are released as homo-
dimers only.1–3 Whereas PDGF-BB is a ligand for all receptor
types, PDGF-DD binds to the PDGF bb- but not the aa-
receptor. PDGF-DD is produced as latent factor. Proteolytic
cleavage of a CUB-domain from each chain is then required
for activation.4 In addition, PDGF-DD differs from PDGF-
BB in that its C-terminus lacks a basic amino-acid sequence
that mediates binding to the extracellular matrix.4
The PDGF receptor possesses tyrosine kinase activity and
is autophosphorylated upon ligand binding.5 The receptor
then interacts with several other cytoplasmic proteins
containing Src homology 2 (SH2) domains, including
phospholipase C (PLC-g), ras guanine 50-triphosphatase-
activating protein, phosphatidyl-inositol 3-kinase (PI3K),
members of the pp60src family of protein tyrosine kinase,
tyrosine phosphatase SHP-2, and members of the signal
transducers and activators of transcription (STAT) family.5
Second messengers include inositol-(1,4,5)-triphosphate and
diacylglycerol, intracellular calcium release, and protein
kinase C (PKC) activation.5
Mesangial cells have repeatedly been shown to express
both PDGF a- and b-receptor subunits.6–11 PDGF-AA usually
elicits lower-level and fewer biological effects in mesangial
cells in comparison to PDGF-BB.6,11 Nevertheless, mesangial
cells are clearly responsive to both growth factor isoforms in
vitro, demonstrating the functional relevance of both the
PDGF a- and b-subunits in these cells. Given that PDGF-DD,
like the PDGF B-chain, can bind to the bb- and ab-receptor,
their biological activities in the kidney may be similar, albeit
not identical in view of their differential binding to the PDGF
aa-receptor. Neither PDGF-B nor -D are normally expressed
in the glomerular mesangium, but both are markedly up-
regulated during human and experimental nephritis.7,12,13 In
view of the above we asked, whether the effects of PDGF-BB
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and -DD on primary human mesangial cells (HMCs) differ
in terms of signal transduction and regulation of gene
expression.
RESULTS
PDGF-BB and -DD induce proliferation in primary HMCs
In pilot studies, a fourfold higher PDGF-DD concentration
showed similar biological activity as PDGF-BB (Table 1a),
which correlates with a threefold difference in receptor
affinity between the two isoforms.1 Based on these pilot
studies, we initially used 50 ng/ml PDGF-BB and 200 ng/ml
PDGF-DD in the experiments (in a later set of experiments
using different batches of both recombinant PDGF-BB and
PDGF-DD, concentrations were changed to 10 and 100 ng/
ml, respectively, to again yield equipotency in the mitogenesis
assay (Table 1b)).
Using the above concentrations, we first verified that
50 ng/ml PDGF-BB and 200 ng/ml PDGF-DD indeed exerted
the same mitogenic effect when studied over a time course of
up to 48 h (Figure 1). Co-stimulation of the cells with these
concentrations of PDGF-BB and -DD failed to exert any
additive or synergistic effects (Figure 1).
PDGF-BB and -DD downregulate the expression of the PDGF
receptor b-chain mRNA in HMCs
In unstimulated HMCs mRNA, expression of the a- and
b-receptor subunits was detected by real-time polymerase
chain reaction (PCR) (Figure 2). If stimulated with PDGF-BB
and/or –DD, a significant suppression of the PDGF receptor
b-chain mRNA expression level occurred, whereas the
expression of the a-chain remained unchanged (Figure 2).
PDGF-BB and -DD induce similar signaling pathways
Activation by PDGF-BB results in the induction of three
major signaling pathways, the mitogen-activated protein
kinase (MAPK)-, Janus kinase (JAK)/STAT-, and PI3K
pathways.11,14,15 Until now nothing is known about the
signaling mechanisms of PDGF-DD, which binds more
selectively to the PDGF-receptor b-chain than PDGF-BB.
As demonstrated in Figure 3a, both Western blot analysis
for phoshorylated (i.e. activated) extracellular signal-regu-
lated kinase 1/2 (ERK1/2) and a functional ERK1/2 kinase
Table 1 | Cell proliferation measured via BrdU incorporation after stimulation of HMCs with PDGF-BB and/or -DD for 24 h using
two different preparations of PDGF-BB and -DD
Growth factor concentration 0 10 ng/ml 50 ng/ml 100 ng/ml 200 ng/ml 400 ng/ml
(a) First batch
PDGF-BB 77743 170733 2167129 n.d. n.d.
PDGF-DD 77743 54712 118720 181768 2307120
(b) Second batch
PDGF-BB 98710 399720 326730 320780 n.d. n.d.
PDGF-DD 98710 n.d. 260720 417750 425760 405750
Data (induction of proliferation as % of unstimulated HMCs) are means7s.d. of four independent experiments (n.d.: not determined).
BrdU, 5-bromo-20-deoxyuridine; HMCs, human mesangial cells; PDGF, platelet-derived growth factor.
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Figure 1 | PDGF-BB and/or -DD induce mesangial cell prolifera-
tion. Cell proliferation was measured via BrdU incorporation after
stimulation of HMCs with PDGF-BB and/or -DD. Data are means7s.d.
of four independent experiments. In the case of unstimulated control
values, means of the absolute BrdU incorporations per time point
were calculated and set as 100%. Over the course of the 48 h of the
experiment, these means of the absolute BrdU incorporations did not
change significantly (data not shown).
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Figure 2 | Expression of the PDGF receptor chains a and b.
Real-time PCR-based expression data normalized to GAPDH mRNA.
The gene expression data from unstimulated and PDGF-BB and/or
–DD-stimulated HMCs are shown. Data are means7s.d. of eight
independent experiments. *Indicates Po0.05 versus unstimulated
control.
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assay demonstrated that PDGF-DD, like PDGF-BB, activates
ERK1/2, albeit with lesser efficiency at the concentrations
used. By electrophoretic mobility shift assay, we also found
activated STAT1 and 3 in response to stimulation with either
PDGF, again with a somewhat weaker response to PDGF-DD
(Figure 3b).
The involvement of the MAPK, JAK/STAT, and PI3K
signaling pathways in mediating the mitogenic properties of
PDGF-BB and -DD was further evaluated in proliferation
assays with primary HMC by using specific inhibitors
(Figure 4). The PDGF-BB induced proliferation can be
inhibited by a pre-incubation with U0126 for 10 min.15
Although pre-incubation times of 30 or 60 min have been
described for AG490 and LY294002,16–20 in our hands both
inhibitors prevented PDGF-induced cell proliferation after a
pre-incubation time of 10 min. Therefore, HMCs were pre-
incubated with all inhibitors used for 10 min before
stimulation with PDGF-BB and/or -DD. Blockade of any of
the three pathways blunted the proliferation induced by
either PDGF-BB or PDGF-DD at all inhibitor concentrations
employed, indicating that both PDGF isoforms use the same
pathways to induce cell proliferation.
Identification of genes differentially regulated by PDGF-BB
and -DD in primary HMCs by cDNA microarray analysis
The gene expression profile of growth-arrested HMCs, as well
as PDGF-BB and/or –DD-stimulated HMCs, was analyzed
after 24 h stimulation by Affymetrix gene chip analysis. Both
growth factors regulated the mRNA expression of several
genes involved in cell proliferation like GAP43, RGS-2, IGF-2,
LTBP-1, LTBP-2, CDC20, TGFb-1, and PRC1 but no differ-
ences between the two PGDFs evolved. Table 2 summarizes
the genes that were classified as being up- or downregulated
by only one PDGF isoform or in the co-stimulation. Eighteen
genes and five unspecified transcripts, as expressed sequence
tags and hypothetical proteins, were regulated by PDGF-DD
but not by PDGF-BB, whereas 18 genes and 17 unspecified
transcripts were regulated by PDGF-BB only. Seventy-eight
genes and 57 unspecified transcripts were specifically
regulated in the co-stimulation of PDGF-BB and -DD. Based
on their potential pathophysiologic relevance, we then
selected 17 genes (five suppressed by PDGF-DD, seven
induced by PDGF-DD, and five induced by PDGF-BB) for
subsequent analysis using real-time reverse transcriptase PCR
(RT-PCR) and complementary DNA (cDNA) isolated from
PDGF-BB and/or -DD-stimulated HMCs (n¼ 8) (Figure 5).
Genes suppressed by PDGF-DD. A significant suppression
could be confirmed for renin–angiotensin system guanyl
nucleotide releasing protein 1 (RASGRP1), nuclear transcrip-
tion factor Y beta (NFYB), transforming growth factor-b-2
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Figure 3 | PDGF-BB and/or -DD activate MAPKs ERK1/2 and
STAT1/3. (a) Activation of MAPKs ERK1 and ERK2 was measured after
stimulation of HMCs with PDGF-BB and/or -DD (n¼ 2) in a Western
blot specific for phosphorylated ERK1/2 and in a kinase assay with the
ELK protein as a substrate. Both PDGF-BB and -DD phosphorylate and
activate ERK1/2. (b) The activation of STAT 1/3 was measured in an
electro-mobility shift assay with nuclear extracts of HMCs stimulated
with PDGF-BB and/or -DD (n¼ 3). Both factors activate STAT 1/1
homodimers, STAT 1/3 heterodimers, and STAT3/3 homodimers;
however, PDGF-BB appeared to be more efficient in this assay.
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Figure 4 | PDGF-BB and -DD use the same intracellular pathways
for mediation of the proliferation signal. HMCs proliferation was
measured by BrdU incorporation after stimulation with PDGF-BB or
-DD. ERK1/2 activation was inhibited by 5 and 25 mM U0126, the JAK/
STAT pathway was blocked by 50 and 100mM AG490, and signaling
through PI3K was blocked by 5 and 20 mM LY294002. Incubation with
different concentrations of inhibitors for the three major signaling
pathways of PDGF-BB prevents the mitogenic effect of PDGF-BB and
-DD, indicating that both activate the same pathways. Data are
means7s.d. of five independent experiments.
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Table 2 | Identification of genes whose expression is changed significantly (Po0.001) by PDGF-BB and/or -DD
Genbank Acc. Gene
Transcripts suppressed by PDGF-DD only
NM_005739,2 RAS guanyl releasing protein 1 (calcium and DAG-regulated) (RASGRP1)
NM_006166,2 Nuclear transcription factor Y, beta (NFYB)
M19154,1 Transforming growth factor-beta-2
NM_003062,1 Slit (Drosophila) homolog 3 (SLIT3)
M22865,1 Cytochrome b5
M31159,1 Growth hormone-dependent insulin-like growth factor-binding protein
Transcripts suppressed by PDGF-BB only
NM_002510,1 Glycoprotein (transmembrane) nmb (GPNMB)
BC002700,1 Similar to keratin 7, clone MGC:3625
Transcripts suppressed by PDGF-BB+PDGF-DD only
NM_005410,1 Selenoprotein P, plasma, 1 (SEPP1)
NM_002667,1 Phospholamban (PLN)
NM_005019,1 Phosphodiesterase 1A, calmodulin-dependent (PDE1A)
L35594,1 Human autotaxin
NM_016201,1 Leman coiled-coil protein (LCCP)
NM_005204,1 Mitogen-activated protein kinase kinase kinase 8 (MAP3K8)
M18767,1 Human complement subcomponent C1s, alpha- and beta-chains
NM_003494,1 Dysferlin, limb girdle muscular dystrophy 2B (DYSF)
NM_002222,1 Inositol 1,4,5-triphosphate receptor, type 1 (ITPR1)
NM_001078,1 Vascular cell adhesion molecule 1 (VCAM1)
NM_003882,1 WNT1 inducible signaling pathway protein 1 (WISP1)
NM_004010,1 Dystrophin (muscular dystrophy, Duchenne and Becker types)
NM_000961,1 Prostaglandin I2 (prostacyclin) synthase (PTGIS)
NM_005512,1 Glycoprotein A repetitions predominant (GARP)
L03203,1 Human peripheral myelin protein 22 (GAS3)
M81635,1 Erythrocyte membrane protein mRNA,
NM_000104,2 Cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 (CYP1B1)
NM_030786,1 Intermediate filament protein syncoilin (SYNCOILIN)
AF078077,1 Growth arrest and DNA-damage-inducible protein GADD45beta
NM_002053,1 Guanylate-binding protein 1, interferon-inducible, 67kDa (GBP1)
NM_014583,1 LIM and cysteine-rich domains 1 (LMCD1)
NM_016277,1 RAB23, member RAS oncogene family (RAB23)
NM_001343,1 Disabled (Drosophila) homolog 2 (DAB2)
NM_016270,1 Kruppel-like factor (LOC51713)
L38969,1 Thrombospondin 3 (THBS3)
AF138303,1 Decorin D
NM_016147,1 Protein phosphatase methylesterase-1 (PME-1)
NM_000861,2 Histamine receptor H1 (HRH1)
M60485,1 Human fibroblast growth factor receptor
NM_015987,1 Heme-binding protein (HEBP)
NM_007216,1 Alpha integrin-binding protein 63 (KIAA1017)
NM_001387,1 Dihydropyrimidinase-like 3 (DPYSL3)
AF188298,1 Disabled 2 p93 (DAB2)
NM_003330,1 Thioredoxin reductase 1 (TXNRD1)
NM_000297,1 Polycystic kidney disease 2 (autosomal dominant) (PKD2)
NM_018450,1 Uncharacterized bone marrow protein BM029 (BM029)
NM_021630,1 PDZ-LIM protein mystique (LOC59346)
Transcripts induced by PDGF-DD only
NM_001211,2 Budding uninhibited by benzimidazoles 1 (yeast homolog), beta (BUB1B)
BC005247,1 Isopentenyl-diphosphate delta isomerase, clone MGC:12281
AF003934,1 Prostate differentiation factor
NM_005542,1 Insulin induced gene 1 (INSIG1)
NM_001673,1 Asparagine synthetase (ASNS)
NM_000269,1 Non-metastatic cells 1, protein (NM23A) expressed in (NME1)
BC003573,1 Farnesyl-diphosphate farnesyltransferase 1, clone MGC:2200
BC001312,1 Protein disulfide isomerase-related protein, clone MGC:5517
NM_003887,1 Development and differentiation enhancing factor 2 (DDEF2)
U18197,1 ATP: citrate lyase
NM_017567,1 N-acetylglucosamine kinase (HSA242910)
NM_001360,1 7-Dehydrocholesterol reductase (DHCR7)
Transcripts induced by PDGF-BB only
NM_002427,2 Matrix metalloproteinase 13 (collagenase 3) (MMP-13)
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(TGF-b2), homo sapiens slit homolog 3 (Drosophila) (SLIT3)
and cytochrome B5 (Figure 5b). However, in contrast to the
microarray analysis, the gene suppression was not specific for
PDGF-DD, but also detected following PDGF-BB and PDGF-
BB plus -DD stimulation.
Genes induced by PDGF-DD. None of the seven genes
induced by PDGF-DD only in the microarray experiment
could be verified by RT-PCR (Figure 5c).
Genes induced by PDGF-BB. By RT-PCR, three genes,
namely cathepsin L (CTSL), matrix metalloproteinase 13
Genbank Acc. Gene
AF191653,1 Diphosphoinositol polyphosphate phosphohydrolase type 2 beta (NUDT4)
NM_004398,2 DEADH (Asp-Glu-Ala-AspHis) box polypeptide 10 (RNA helicase) (DDX10)
NM_004995,2 Matrix metalloproteinase 14 (membrane-inserted) (MMP-14)
BC003143,1 Dual specificity phosphatase 6, clone MGC:3789
NM_021127,1 Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1)
NM_002712,1 Protein phosphatase 1, regulatory subunit 7 (PPP1R7)
AF348514,1 Fetal thymus prothymosin alpha
NM_005013,1 nucleobindin 2 (NUCB2)
AF306765,1 Junctate mRNA
AF318616,1 Synaptojanin 2 mRNA
NM_005475,1 Lymphocyte adaptor protein (LNK)
NM_001912,1 Cathepsin L (CTSL)
J03202,1 Laminin B2 chain
AB014486,1 mRNA for RA70
U67195,1 Tissue inhibitor of metalloproteinase-3
Transcripts induced by PDGF-BB + -DD only
NM_012323,1 v-maf musculoaponeurotic fibrosarcoma (avian) oncogene family F (MAFF)
NM_004267,1 Carbohydrate (chondroitin 6keratan) sulfotransferase 2 (CHST2)
NM_006823,1 Protein kinase (cAMP-dependent, catalytic) inhibitor alpha (PKIA)
NM_014705,1 KIAA0716 gene product (KIAA0716)
NM_001394,2 Dual specificity phosphatase 4 (DUSP4)
AY029180,1 Soluble urokinase plasminogen activator receptor precursor (SUPAR)
NM_000216,1 Kallmann syndrome 1 sequence (KAL1)
NM_001423,1 Epithelial membrane protein 1 (EMP1)
NM_004434,1 Echinoderm microtubule-associated protein-like (EMAPL)
NM_006579,1 Emopamil-binding protein (sterol isomerase) (EBP)
NM_003824,1 Fas (TNFRSF6)-associated via death domain (FADD)
NM_005308,1 G protein-coupled receptor kinase 5 (GPRK5)
AF031463,1 Phosducin-like protein mRNA
NM_016020,1 CGI-75 Protein
BC000425,1 Protein disulfide isomerase related protein, clone MGC:8346
M73554,1 bcl-1 mRNA
AF260566,1 Hepatocyte growth factor-regulated tyrosine kinase substrate, isoform 2 (HRS)
AF006011,1 Dishevelled 1 (DVL1) mRNA
NM_001283,1 Adaptor-related protein complex 1, sigma 1 subunit (AP1S1)
U84246,1 Lysosomal sialidase
AF074979,1 Regulator of G protein signaling-Z (RGSZ1) mRNA
NM_016031,1 Elongation of very long chain fatty acids-like 1 (ELOVL1)
NM_016072,1 CGI-141 protein (LOC51026), mRNA
NM_002004,1 Farnesyl diphosphate synthase
M23612,1 Human GTPase-activating protein (GAP)
AF167438,1 Androgen-regulated short-chain dehydrogenasereductase 1 (ARSDR1)
BC000478,1 Heat shock 70kDa protein 9B (mortalin-2)
L13386,1 (clone 47) Miller–Dieker lissencephaly protein (LIS1)
NM_002708,1 Protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA)
AB029156,1 HRP-3
NM_016185,1 Hematological and neurological expressed 1 (HN1)
NM_002658,1 Plasminogen activator, urokinase (PLAU)
NM_005742,1 Protein disulfide isomerase-related protein (P5)
AF064238,3 Smoothelin large isoform L2 (SMTN)
NM_001069,1 Tubulin, beta polypeptide (TUBB)
NM_013417,1 Isoleucine-tRNA synthetase (IARS)
BC000498,1 Glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1)
NM_004181,1 Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) (UCHL1)
AF015040,1 NUMB protein (NUMB) mRNA
AF257318,1 SH3-containing protein SH3GLB1
NM_004447,1 Epidermal growth factor receptor pathway substrate 8 (EPS8)
Table 2 | Continued
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(MMP-13), and MMP-14, exhibited a significant induction
following stimulation with PDGF-BB, PDGF-BB plus -DD,
but not with PDGF-DD alone (Figure 5a). However, in the
particular case of MMP-13, a trend towards increased mRNA
expression after stimulation with PDGF-DD alone was
notable (Figure 5a).
Thus, all genes that were modulated by PDGF-DD were
also found to be regulated by PDGF-BB in the verification
RT-PCR studies. Vice versa, at least in four cases gene
induction appeared to be specific for PDGF-BB.
In further studies, we focussed on the two genes that
exhibited the most pronounced regulation by PDGF-BB and
the most pronounced differences between PDGF-BB and
-DD, that is, MMP-13 and -14.
Stimulation with PDGF-BB and -DD results in the secretion of
pro-MMP-13
MMP-13 showed the highest mRNA induction after
stimulation with PDGF-BB and appeared to be relatively
specifically induced by PDGF-BB only (Figure 5a). Therefore,
we assessed secretion of the MMP-13 protein into the culture
supernatant of PDGF-BB and/or –DD-activated HMCs. As
shown in Figure 6, PDGF-BB resulted in a time- and dose-
dependent increase of secreted pro-MMP-13. Unlike the
mRNA results, PDGF-DD was an equally potent inducer of
MMP-13 release (Figure 6). No synergistic or additive effects
between PDGF-BB and -DD were observed at the concentra-
tions assayed.
Stimulation of HMCs with PDGF-BB and -DD induces
expression and activation of the MMP-14 protein
MMP-14 mRNA expression also appeared to be specifically
regulated by PDGF-BB in both the micro-array and the
RT-PCR confirmation experiments. As MMP-14 is not
secreted into the culture supernatant but remains cell
associated, we studied its protein expression by Western blot
analysis using a monoclonal MMP-14 antibody, which
recognizes inactive as well as active MMP-14. The data
showed that both PDGF-BB and -DD increased levels of
activated MMP-14 protein in lysates of HMCs (Figure 7). In
addition, the incubation of HMC with both PDGF-BB and -
DD resulted in increased levels of total MMP-14 protein (i.e.
inactive plus active MMP-14; Figure 7).
DISCUSSION
In the present study, we focused on potential differences in
the biological functions of PDGF-BB and PDGF-DD in
human mesangial cells. Both PDGFs are potent mediators of
mesangial cell proliferation in vitro and in vivo. Additional
functions of PDGF-BB may be expected by the binding of
PDGF-BB to the PDGF aa-receptor, whereas PDGF-DD can
only activate the PDGF bb- and possibly also the ab-receptor.
At the aa-receptor, PDGF-DD failed to compete with the
binding of labeled PDGF-AA.1,2,21,22 We therefore first
verified that our primary HMCs expressed both PDGF
receptor subunits. In these experiments, it was notable that
both PDGF-BB and -DD induced a negative feedback
regulation of the b-receptor subunit mRNA, as had been
described by Oster et al.23 for PDGF-BB, whereas expression
of the a-subunit remained stable after ligand addition.
The most important decision in a study that compares the
biological function of two growth factors is the selection of
agonist concentrations. Bergsten et al.1 demonstrated that
protease activated PDGF-DD, that is, PDGF-DD devoid of
the CUB-domain, had a threefold lower binding capacity to
the b-chain of the PDGF receptor than PDGF-BB. Hence, if
Table 3 | Primers for real-time RT-PCR used for the verification of the HMCs cDNA microarray data
Gene Forward primer Reverse primer
ATP:citrate lyase TCAGGAGGGCTTACGGGTG TCTGTGCCAAAGACATGGATG
ASNS GCATCCGTGGAAATGGTTAAA TCCACATTGTCATAGAGGGCG
BUB1B TCAACAGAAGGCTGAACCACTAGA GCCAACAGAGTTTGCCGAGA
Cathepsin L CGGCTTTGTGGACATCCCT CAGAAATGGGCCCCACAGT
Cytochrome B5 AACAAGCTGGAGGTGACGCT TTGGACATTTCCCTGGCATC
DDEF2 TGTCCAATGCTATGGTCCTGC ATAGAGCGCTTTCACCCGC
DHCR7 ACATGCTCGGCTCTCGGAC AGGTATAGAGCTGGGCGGCT
INSIG1 AGCCCCTACCCCCAACACCT TAGGACCACCCCAACCGAG
Laminin B2 CAGACCAACTCCTAGCCCGA GTATCCCGTCCCTTCTTTGC
MMP-13 GCAGAGCGCTACCTGAGATCA TCATGGAGCTTGCTGCATTC
MMP-14 GGTGAGTCAGGGTTCCCCA TCAGGAACAGAAGGCCGC
NFYB AATTCAGAGAGGCTATGAAAGGAGAA CCTCTGTAAGCTCTTCACTTAGTCCA
NME23A CTACGTTGACCTGAAGGAACCG CGGCCCTGAGTGCATGTAT
RASGRP1 GGCATCTCCCAGTGGGTACA GAGCCACCTGGATGAACTTGA
SLIT GCGCGATTTGGAGATCCTTA TTCGGATCTTCGGCATGTG
TGF-b2 GGGTGGAAATGGATACACGAA TCCATAAATACGGGCATGCTC
TIMP-3 TCCAATTTCGGTTACCCTGG CTGCAGTAGCCGCCCTTCT
PDGF-receptor a-chain CCCTTGGTGGCACCCC CGGTACCCACTCTTGATCTTATTGT
PDGF-receptor b-chain ATGCCTTACCACATCCGCTC ACATTGCAGGTGTAGGTCCCC
GAPDH A`GCCACATCGCTCAGACACC GCGCCCAATACGACCAAA
ASNS, asparagine synthetase; BUB1B, budding uninhibited by benzimidazoles 1 (yeast homolog), beta; DDEF2, development and differentiation enhancing factor 2; DHCR7,
7-Dehydrocholesterol reductase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; INSIG1, insulin induced gene 1; MMP-13, matrix metalloproteinase 13 (collagenase 3);
MMP-14, matrix metalloproteinase 14 (membrane-inserted); NFYB, nuclear transcription factor Y, beta; NME23A, non-metastatic cells 1, protein (NM23A) expressed in (NME1);
PDGF, platelet-derived growth factor; RASGRP1, renin–angiotensin system guanyl releasing protein 1; RT-PCR, reverse transcriptase-polymerase chain reaction; SLIT3, Slit
(Drosophila) homolog 3; TGF-b2, transforming growth factor-beta-2; TIMP, tissue inhibitor of metalloproteinase-3.
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based on weight, equal PDGF-BB and -DD concentrations
will result in different activation of the PDGF receptors,
pretending different biological functions of the two PDGF
isoforms. Since the mitogenic effect of PDGFs on mesangial
cells is almost exclusively mediated by the PDGF b-receptor
subunit,11 we based all experiments of the present study on
PDGF-BB and -DD concentrations, which induced similar
proliferation in HMCs. The validity of this approach was
substantiated by the virtually identical time course of HMCs
growth after stimulation with either PDGF-BB or -DD
(Figure 1).
Using the optimized concentrations, we next investigated
the signaling of PDGF-DD in comparison to PDGF-BB.
PDGF-BB is able to activate MAPK, JAK/STAT, PI3K, and
phospholipase C pathways.11,15,24 Until now nothing was
known about the signaling of PDGF-DD. We assessed
activation of ERK1/2, that is, the MAPK pathway, and the
activation of STAT 1/3. Both signaling pathways were found
to be activated by PDGF-DD similarly to PDGF-BB, albeit at
lower potency. Proliferation assays using inhibitors for the
MAPK-, JAK/STAT-, or PI3K-pathway confirmed their
involvement. These findings are similar to a study comparing
the signaling of PDGF-AA and -BB in rat metanephric
mesenchymal cells,25 which showed that despite different
receptor binding, PDGF-AA and -BB stimulated the same
signaling pathways.
Next, we looked for genes differentially regulated by
PDGF-BB and -DD by gene chip analysis. Out of 17 genes,
which appeared to be regulated by either PDGF-BB or -DD
but not both, only four (MMP-13, MMP-14, cathepsin L, and
cytochrome B5) could be verified by real-time RT-PCR.
Importantly, using RT-PCR, we were able to show that all
genes regulated by PDGF-DD were also regulated by -BB and
no case of an exclusive PDGF-DD-regulated gene was
observed in this study. This observation is in agreement with
the current model of differential PDGF isoform binding to
the receptors.1,2,21,22 Of the four genes that appeared to be
regulated by PDGF-BB only, cathepsin L and cytochrome B5
were not pursued further in view of their weak mRNA
induction following stimulation with PDGF-BB.
The gene that showed the strongest induction of mRNA
expression in response to PDGF-BB was MMP-13. Interest-
ingly, MMP-13 is a known target gene for STAT1,26
confirming the different activation of the STAT1/3 signalling
pathway by PDGF-BB and -DD. This finding is supported by
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Figure 5 | Verification of the array results. Real-time PCR-based
expression data normalized to the internal standard GAPDH mRNA.
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the regulation of TIMP-3 (a target gene of STAT126) by
PDGF-BB (Table 2). In addition, the mRNA expression of the
STAT3 target gene junB27 was specifically induced by PDGF-
BB in at least one of the three array experiments. MMP-13
(collagenase III) is expressed in pathological situations such
as inflammation or cancer and degrades type I, II, III, and IV
collagen, gelatin, aggrecan, perlecan, the large isoform of
tenascin C, fibrillin, and fibrinogen.28 However, when we
measured pro-MMP-13 protein secretion after stimulation of
HMC with PDGF-BB and/or -DD, both growth factors were
able to induce its secretion. Once again, no absolute PDGF-
BB specificity of the biological response could be established.
The divergent results of the MMP-13 mRNA analyses and
protein data may result from the failure of a low-grade
induction of MMP-13 mRNA by PDGF-DD (Figure 5) to
reach statistical significance. Alternatively, PDGF-DD may
affect MMP-13 at the post-transcriptional level, since a
discrepancy between the induction of the MMP-13 mRNA
levels and expression of the protein has also been noted by
others.29
The second gene that appeared to be specifically regulated
by PDGF-BB in vitro was MMP-14. MMP-14 (membrane
type 1-MMP) family belongs to the MT-MMP family and
degrades fibrillar collagens, that is, type I, II, and III
collagens, as well as gelatin, proteoglycan, fibronectin,
vitronectin, type 1 and 5 laminin, and aggrecan.30 Addition-
ally, MMP-14 is able to activate pro-MMP2, pro-MMP9, and
pro-MMP-13.31 Until now high glucose levels were the only
known regulator of MMP-14 mRNA expression in mesangial
cells, indicating an involvement in matrix accumulation in
diabetic nephropathy.32,33 Interestingly, MMP-14 can mod-
ulate PDGF-B binding to the PDGF receptor b and thereby
increase signal transduction in vascular smooth muscle
cells.34 MMP-14-deficient cells show defective responses
towards PDGF-B with regard to cell proliferation, chemo-
taxis, and activation of ERK1/2 and Akt, supporting the
notion that MMP-14 is a mediator of PDGF-BB effects.34
Taken together with our finding of a PDGF-B inducible
MMP-14 expression, this would indicate an positive auto-
regulatory loop. Also of relevance to the present data is
the observation that MMP-14 mRNA is overexpressed in
the expanded mesangium of the anti-Thy 1.1 nephritis
model in rats.35 Given that this model is PDGF-B mediated,35
our data provide a mechanistic explanation for the
in vivo observations of Hayashi et al.35 In contrast to the
apparently PDGF-BB-specific induction of MMP-14
mRNA in HMCs, at the protein level, MMP-14, like MMP-
13, was equally induced by both PDGF isoforms. This again
raises the issue of potential post-translational regulation,
since it is known that the expression and activation of
MMP-14 is regulated by proteolytic processing, shedding,
endocytosis, degradation, recycling, and formation of
homodimers.36
In summary, stimulation of HMC with PDGF-DD
resulted in qualitatively very similar biological responses in
comparison to PDGF-BB. Whether the two PDGF isoforms
result in a quantitatively different activation of individual
signaling pathways remains difficult to prove given the
problem of establishing ‘bioequivalent’ concentrations of the
agonists, which contain important structural differences such
as the presence of a latency-inducing CUB domain in PDGF-
DD but not -BB. Nevertheless, our gene array data also
pointed to rare instances of genes, where mRNA expression
appeared to be regulated by PDGF-BB only. However,
at the protein level, the two most apparently PDGF-BB-
specific genes, that is, MMP-13 and -14, were similarly
induced by PDGF-BB and -DD. It is therefore conceivable
that higher doses of PDGF-DD might have led to a similar
gene induction as PDGF-BB in the array studies, since
biological equipotency as defined for proliferation may
not be the same for other biological effects. Taken together,
our data suggest that in HMCs PDGF-BB and -DD induce
very similar biological responses, implying that both
PDGF isoforms almost exclusively mediate their action
in the glomerular mesangium via the PDGF b-receptor
subunit.
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MATERIALS AND METHODS
Reagents and HMCs
Recombinant human PDGF-DD lacking the CUB domain was
produced as described.2 PDGF-BB was purchased from Sigma-
Aldrich (Deisenhofen, Germany). Primary HMCs were obtained
from Cambrex (Verviers, Belgium) and were maintained as
described.37
Proliferation assays
To compare the effects of PDGF-BB and -DD, HMCs were seeded in
96-well plates (Nunc, Wiesbaden, Germany), grown to subcon-
fluence, and growth-arrested for 24 h in modified Czapek Dox broth
(MCDB) medium (Sigma-Aldrich). After 24 h, PDGF-DD (200 ng/
ml), PDGF-BB (50 ng/ml), or PDGF-DD (200 ng/ml) plus PDGF-
BB (50 ng/ml) were added and the cells were incubated for 4 to 48 h.
DNA synthesis was determined during the last 4 h by a 5-bromo-20-
deoxyuridine (BrdU) incorporation assay according to the manu-
facturer’s instructions (Roche, Mannheim, Germany). In other
experiments, pharmacological inhibitors were added to the medium
10 min prior to stimulating HMCs with PDGF-DD (200 ng/ml) or
PDGF-BB (50 ng/ml) for 24 h: U0126 (inhibits the ERK-activating
kinases (mitogen-activated protein kinase/ERK kinase 1 and
mitogen-activated protein kinase/ERK kinase 2) at a final concen-
tration of 5 and 25 mM, AG490 (inhibits the Janus-activated kinase 2)
at a final concentration of 50 and 100mM, and LY294002 (inhibits
the PI3K) at a final concentration of 5 and 20 mM.
Real-time quantitative RT-PCR
Total RNA was isolated from HMCs using the Invisorb Spin Cell-
RNA Mini Kit (Invitek, Berlin, Germany). RNA purity determina-
tion, cDNA synthesis, and RT-PCR were performed as described.12
The primer sequences are listed in Table 3. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal
standard.
Western blot analysis
Subconfluent HMCs were growth arrested for 24 h in MCDB media.
After 24 h, PDGF-DD (200 ng/ml), PDGF-BB (50 ng/ml), or PDGF-
DD (200 ng/ml) together with PDGF-BB (50 ng/ml) in RPMI 1640
with 100 mg/ml of streptomycin and 100 U/ml penicillin were added
and the cells were incubated for 2–30 min. Subsequently, the cells
were washed in ice-cold phosphate-buffered saline and lysed in
700ml Triton X-100 lysis buffer as described.15 After 5 min, cells were
scraped with a cell lifter and centrifuged at 41C for 15 min at
10 000 g. The soluble cell lysates were separated and blotted as
described15 and probed with polyclonal antibodies against the
carboxy-terminal peptide of p42 ERK.15 The primary antibodies
(diluted 1:1000) were detected using horseradish peroxidase-
conjugated protein A visualized by the Amersham ECL system after
intensive washing of the membrane.
The Western blot analysis for MMP-14 was performed as
described above after stimulation of HMCs with PDGF-BB and/or
-DD for 24 h. Blots were probed with a monoclonal MT1-MMP
(160–173) antibody (Calbiochem, Schwalbach, Germany). For
normalization, membranes were stripped (2 30 min incubation
in 200 mM glycine, 0.1% SDS, 1% Tween 20, pH 2.2) and reprobed
with a monoclonal anti-actin antibody (clone C-2, Santa Cruz).
Nonradioactive ERK activity assay
Soluble cell lysates (500 mg) were blotted and probed as described.15
EMSA
Following HMCs stimulation (see above), the supernatant was
removed, nuclear extracts were isolated and probed to a double-
stranded mutated SIE oligonucleotide from the c-fos promotor
(m67SIE: 50-GAT CCG GGA GGG ATT TAC GGG AAA TGC TG-30)
as described.38
Affymetrix gene chip array
HMCs were cultured in 75 cm2 flasks until subconfluency, growth
arrested for 24 h, and subsequently stimulated with PDGF-BB
(10 ng/ml), PDGF-DD (100 ng/ml), PDGF-DD (100 ng/ml) together
with PDGF-BB (10 ng/ml), or with RPMI 1640 alone in the presence
of 100 mg/ml of streptomycine and 100 U/ml penicillin for 24 h. The
difference in PDGF concentrations in these experiments as
compared to the experiments described above resulted from the
usage of a new PDGF preparation for the array studies. As above, the
growth factor concentrations used for the chip assay lead to
equipotent induction of HMCs proliferation (Table 1). After
cultivation for 24 h, the cells were lysed and RNA was isolated
using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA sample
collection and generation of biotinylated complementary RNA
probes was carried out essentially as described in the Affymetrix
GeneChip Expression Analysis Technical Manual (Affymetrix, Santa
Clara, CA, USA). Total RNA (10 mg) was reverse transcribed into
double-stranded cDNA using HPLC-purified T7-(dt) 24 primers
(MWG, Ebersberg, Germany) and the Superscript choice cDNA
synthesis system (Invitrogen Corp., Carlsbad, CA, USA). Subse-
quently, the purified double-stranded cDNA was used as template to
synthesize biotinylated complementary RNA probes using the
BioArray High Yield RNA Transcription Labeling Kit (Enzo
Diagnostics, Enzo Life Science Inc., Farmingdale, NY, USA). Each
sample was hybridized to an Affymetrix human Genome U133A
microarray for 16 h at 451C. Expression values of each probe set
were determined and samples stimulated with PDGF-BB, PDGF-
DD, or PDGF-BB plus -DD were compared with unstimulated
samples using the Affymetrix Microarray Suite 5.0 software. The
intensities across multiple arrays were normalized to a target
intensity of 2500 using global normalization scaling. Three separate
experiments were performed under identical conditions. Genes,
whose expression levels were changed significantly (Po0.001) in at
least two of three experiments, were considered to be regulated by
the stimulus.
ELISA for pro-MMP-13
Cells (20 000–40 000) were seeded in each well of a 12-well plate,
growth arrested for 24 h, and treated with 1, 10, or 100 ng/ml PDGF-
BB, 10, 100, or 500 ng/ml PDGF-DD, or 10 ng/ml PDGF-BB plus
100 ng/ml PDGF-DD as described. The conditioned media were
harvested at 24 and 48 h and centrifuged at 10000 r.p.m. for 4 min.
The supernatants were assayed using to the R&D Systems
Quantikine ELISA kit for the detection of pro-MMP-13.
Statistical analysis
All values are expressed as means7s.d. Statistical significance
(defined as Po0.05) was evaluated using analysis of variance and
Bonferroni t-tests.
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